On October 13, at the 2026 Annual Meeting of the American Society for Bone & Mineral Research (ASBMR), in a plenary poster presentation, Edward Hsiao, MD, PhD, Professor and Director of the UCSF Metabolic Bone Clinic at the University of California, San Francisco, presented baseline characteristics of patients with FOP in ANDECAL-1.

The poster presentation included the first disclosure of efficacy results from ANDECAL-1, with preliminary data showing an 86.2% reduction in the new flare-up rate (compared to 6 months prior to baseline) with andecaliximab at 300mg/week.

We are grateful to the 12 people with FOP ages 12+ living in the United States who enrolled in Part 1 of the ANDECAL Phase 2/3 Trial.

Read ãshibio's press release about the ASBMR plenary poster presentation